CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 122 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q1 2023. The put-call ratio across all filers is 1.34 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,314,160,084 | -31.3% | 60,199,729 | 0.0% | 42.08% | +46.6% |
Q2 2023 | $1,913,749,385 | +129310.3% | 60,199,729 | -0.7% | 28.70% | +6.6% |
Q1 2023 | $1,478,823 | -22.7% | 60,632,356 | 0.0% | 26.92% | -35.1% |
Q4 2022 | $1,912,345 | -99.9% | 60,632,356 | 0.0% | 41.46% | +0.2% |
Q3 2022 | $1,713,470,000 | +6.9% | 60,632,356 | 0.0% | 41.39% | +23.4% |
Q2 2022 | $1,603,119,000 | -24.5% | 60,632,356 | 0.0% | 33.55% | +9.2% |
Q1 2022 | $2,122,739,000 | +8.0% | 60,632,356 | 0.0% | 30.71% | +30.7% |
Q4 2021 | $1,965,701,000 | +9.9% | 60,632,356 | 0.0% | 23.51% | +11.4% |
Q3 2021 | $1,788,655,000 | +15.1% | 60,632,356 | 0.0% | 21.09% | +39.1% |
Q2 2021 | $1,553,401,000 | +86.6% | 60,632,356 | 0.0% | 15.17% | +23.8% |
Q1 2021 | $832,482,000 | -17.2% | 60,632,356 | 0.0% | 12.25% | -67.8% |
Q4 2020 | $1,005,284,000 | – | 60,632,356 | – | 38.09% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,965,701,000 | 23.51% |
Affinity Asset Advisors, LLC | 225,000 | $7,295,000 | 2.65% |
Perceptive Advisors | 10,173,454 | $329,822,000 | 2.54% |
Artal Group S.A. | 1,500,000 | $48,630,000 | 1.32% |
Rock Springs Capital Management LP | 1,648,435 | $53,442,000 | 1.24% |
RTW INVESTMENTS, LP | 666,666 | $21,613,000 | 0.32% |
BOULDER HILL CAPITAL MANAGEMENT LP | 8,900 | $289,000 | 0.28% |
EAM Investors, LLC | 39,907 | $1,294,000 | 0.21% |
FEDERATED HERMES, INC. | 3,113,333 | $100,934,000 | 0.19% |
Alkeon Capital Management | 1,909,035 | $61,891,000 | 0.12% |